Jenny Zeng's Amazon Bestseller ‘Empowering Emotions' Introduces the C.A.L.M Framework
Jenny Zeng, a seasoned emotional coach and psychologist, has released her latest book, , which has achieved Amazon #1 bestseller status in categories such as Teen Health, Self-Help for Anxiety & Phobias, and Children's Health.
This comprehensive guide offers readers practical strategies to manage emotional struggles, including anxiety, depression, PTSD, and obsessive-compulsive disorder (OCD), through the implementation of the C.A.L.M framework, Controlling breathing, Address thoughts, Let go of tension, and Mindfulness.
According to the , in 2019, approximately 970 million people worldwide were living with a mental disorder, with anxiety and depressive disorders being the most common. Zeng's C.A.L.M framework provides readers with scientifically supported self-regulation techniques aimed at fostering long-term emotional resilience.
Drawing from her personal experiences with anger mismanagement and psychological distress, Zeng shares how unresolved emotions can lead to significant physiological and psychological consequences. Her journey toward self-healing, which included hospitalization due to extreme headaches, inspired the development of the strategies now outlined in her book.
Grounded in cognitive-behavioral therapy (CBT), emotion-focused therapy (EFT), and mindfulness-based interventions, Empowering Emotions provides a structured self-management system for individuals struggling with emotional challenges.
The book also includes real-world case studies demonstrating how people have successfully applied C.A.L.M techniques to overcome anger, anxiety, and trauma, highlighting its broad applicability across different psychological conditions.
Mental health professionals and readers alike have praised Empowering Emotions for its clear, step-by-step guidance, positioning it as a valuable resource for those seeking lasting emotional stability.
For more details or to purchase Empowering Emotions, visit .
About Jenny Zeng
Jenny Zeng is an emotional coach and psychologist with over 20 years of experience in healthcare. Specializing in emotional regulation, trauma healing, and cognitive-behavioral strategies, she is dedicated to making mental health solutions accessible to individuals worldwide.
###
For more information about Jenny Zeng - Salt N Light Consulting, contact the company here:Jenny Zeng - Salt N Light ConsultingJenny Zengsaltnlight.consulting@gmail.comSingapore
CONTACT: Jenny Zeng
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
25 minutes ago
- Hamilton Spectator
Eleos Deepens Post-Acute Care Mission with Home Health, Palliative, and Hospice Care Expansion
CHICAGO and BOSTON, July 28, 2025 (GLOBE NEWSWIRE) — Eleos Health, the market leader in AI for behavioral health, announced its expansion deeper into post-acute care, bringing its trusted, purpose-built AI platform to home health, palliative care and hospice settings. At the 2025 National Alliance for Care at Home Financial Summit on July 28 in Chicago, Eleos will showcase how AI can ease documentation burdens, ensure compliance and improve care quality across the post-acute landscape. By 2034, Americans over the age of 65+ will outnumber children 18 and under. The U.S. home hospice market alone is estimated to reach over $75 billion by 2032. The already heavy documentation burden for in-home care providers will explode as these demographic trends continue unless providers can access innovative tools and solutions. Eleos is trusted by leading behavioral health organizations and care systems across the United States. Its AI-powered platform is designed to work seamlessly with providers' existing workflows — including their preferred EMRs — ensuring zero friction and fast adoption in both clinical and community-based settings. 'Post-acute care providers deliver essential support in deeply human moments,' said Alon Joffe, CEO and Co-founder of Eleos. 'They deserve intelligent tools that make their work easier. Eleos is proud to bring proven purpose-built AI systems to this space, supporting care that's more efficient, compliant and compassionate.' Trusted by Providers, Built for the Field Post-acute providers often face unique barriers: limited time between visits, emotionally complex environments, and growing documentation and compliance demands. Eleos helps them work more efficiently by: Whether following up with a client at home or bedside for hospice care, Eleos empowers post-acute providers to stay present with clients and their families without worrying about quality and billing standards. Proven ROI and Operational Impact Since launching in 2020, Eleos has delivered proven outcomes across its partner organizations, including: By improving efficiency and documentation quality at scale, Eleos helps organizations reduce burnout, minimize delays, confidently prepare for audits and streamline reimbursement cycles. That repeatable ROI — on both the clinical and financial side of care — is essential. Innovative Partners Early Eleos strategic partners in home health, palliative, and hospice are organizations staying ahead of the healthcare AI revolution and regulatory shifts while prioritizing provider needs and exceptional patient care. Partners receive early access to tailored functionality, close collaboration with Eleos' product and clinical teams, and the opportunity to shape how purpose-built AI reimagines the post-acute care space. To meet Eleos at the Care at Home Financial Summit or explore a partnership, contact Isaac Greszes at isaacg@ or sign up for a meeting here . About Eleos At Eleos, we believe the path to better healthcare is paved with provider-focused technology. Our purpose-built AI platform streamlines documentation, simplifies compliance and surfaces deep care insights to drive better client outcomes. Created using real-world care sessions and fine-tuned by our in-house clinical experts, our AI tools are scientifically proven to reduce documentation time by more than 70% and boost client engagement by 2x. With Eleos, providers are free to focus less on administrative tasks and more on what got them into this field in the first place: caring for their clients.
Business Upturn
an hour ago
- Business Upturn
HealthLynked Launches New Enterprise Healthcare Solutions Website and Upgraded Provider Directory to Expand Strategic Value Across the Healthcare Market
NAPLES, Fla., July 28, 2025 (GLOBE NEWSWIRE) — via IBN — HealthLynked Corp. (OTCQB: HLYK ), a pioneer in healthcare technology and patient engagement, today announced the launch of its newly designed Enterprise Healthcare Solutions Website, , along with significant enhancements to its consumer-facing provider directory. These developments further position HealthLynked as a key technology partner for organizations across the healthcare landscape. A Central Hub for Strategic Healthcare Partners The new website serves as a dedicated platform for HealthLynked's commercial partners, showcasing solutions tailored for: Insurance Carriers & TPAs – Streamlined patient engagement, population health tools, and cost-containment services. – Streamlined patient engagement, population health tools, and cost-containment services. Pharmaceutical Companies – Access to real-world data for clinical research, engagement, and recruitment. – Access to real-world data for clinical research, engagement, and recruitment. Advertising & Marketing Firms – Targeted healthcare campaigns leveraging HealthLynked's consumer network. – Targeted healthcare campaigns leveraging HealthLynked's consumer network. ACOs & Healthcare Networks – Technology for coordinated care, data insights, and patient communication. – Technology for coordinated care, data insights, and patient communication. Large Employers & PEOs – Telemedicine access, benefits navigation, and tools for managing employee health costs. 'Our new Enterprise Healthcare Solutions Website is a reflection of our expanding role in the healthcare ecosystem,' said Dr. Michael Dent, CEO of HealthLynked. 'This platform communicates the value we deliver to healthcare stakeholders and reinforces our commitment to scalable solutions that improve outcomes and reduce costs.' Enhanced Provider Directory Empowers Patients with Smarter Tools Alongside the new partner-focused site, HealthLynked has implemented major upgrades to its national provider directory, aimed at enhancing the user experience: Improved Performance – Faster load times and smoother navigation. – Faster load times and smoother navigation. Localized Provider Suggestions – Users viewing a provider profile will now see dynamically generated suggestions for similar providers nearby, increasing care options. These enhancements give patients more flexibility and transparency in choosing providers that fit their specific needs. 'Our mission has always been to improve healthcare access and coordination,' said Dr. Dent. 'The improvements to our platform reflect our continued investment in technology that supports both personalized patient care and enterprise-scale efficiency.' Advancing HealthLynked's Strategic Vision Together, the new Enterprise Healthcare Solutions Website and upgraded provider directory demonstrate HealthLynked's commitment to innovation across all touchpoints—strengthening strategic relationships and empowering consumers with better tools to manage their health. About HealthLynked Corp HealthLynked Corp. is transforming healthcare through a cloud-based platform that connects patients and providers nationwide. With secure medical record management, AI-driven insights, and a robust provider directory, HealthLynked delivers improved access, cost savings, and coordinated care for consumers and enterprise clients alike. Learn More: Download the HealthLynked App: Apple App Store Google Play Store Forward-Looking Statements This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and involve risks and uncertainties that may cause actual results to differ materially. HealthLynked disclaims any obligation to update these statements except as required by law. Media Contact: HealthLynked Corp. 1265 Creekside Parkway, Suite 200 Naples, Florida 34108 [email protected] 1-800-928-7144
Hamilton Spectator
an hour ago
- Hamilton Spectator
Impulse Dynamics® Completes Enrollment of Pivotal Trial for CCM-D® HF System and Earns Category 1 CPT Codes for CCM® Therapy
MARLTON, N.J., July 28, 2025 (GLOBE NEWSWIRE) — Impulse Dynamics®, a global medical device company committed to improving the lives of people with heart failure (HF), announced two major accomplishments, marking an inflection point in the advancement and accessibility of CCM® Therapy. 'We are proud to achieve these two pivotal milestones, which signal the growing acceptance of CCM® Therapy as a core component of HF treatment,' said Jason Spees, CEO of Impulse Dynamics®. 'The progress of the INTEGRA-D™ trial moves forward our path to seek regulatory approval of this first-of-its-kind, combined therapy for HF patients. Additionally, we appreciate the support of the ACC and HRS on our CPT coding initiative, and the AMA's timely review process that opens the door to broader access for patients and providers.' 'Many HF patients are treated with ICDs to protect against sudden death, but most do not treat HF itself. The INTEGRA-D™ trial is focused on evaluating a new device aimed at bridging this treatment gap by delivering symptom relief for HF patients receiving ICDs,' said Niraj Varma, M.D., Ph.D., Professor of Medicine and Director of Cardiac Pacing and Tachyarrhythmia at the Cleveland Clinic, and National Principal Investigator of the INTEGRA-D™ clinical trial. 'Completing enrollment for this trial is an important step towards evaluating this device for patients that could potentially benefit.' Each year, over 100,000 new ICDs are implanted in patients in the United States alone, adding to the estimated 800,000 individuals currently living with these devices (1,2). The CCM-D® HF System represents an important advancement, potentially offering these patients an option to life-saving technology and HF symptom relief. Additionally, the availability of CPT codes has expanded reimbursement pathways for the current Optimizer® device, helping increase access to this therapy for individuals living with heart failure, underscoring the maturation of CCM® therapy from an emerging innovation to a potentially established standard of care for HF patients. Together, these two milestones represent Impulse Dynamics®' unwavering focus on driving meaningful innovation for the millions of patients living with HF. About the INTEGRA-D™ Trial The INTEGRA-D™ trial is a multicenter, prospective, single-arm study evaluating the safety and efficacy of CCM-D® HF System. This April, the initial defibrillation efficacy (DE) cohort results were presented by Dr. Niraj Varma as a late-breaking clinical trial at the 2025 Heart Rhythm conference in San Diego, which marked the completion of the efficacy phase of the trial. The CCM-D® device successfully converted induced ventricular fibrillation (VF) in 100 percent of the enrolled patients in the DE cohort, meeting the primary efficacy endpoint. Once six months of follow-up is completed, the data will be submitted to the U.S. Food and Drug Administration (FDA) in a Premarket Approval (PMA) application. About the Optimizer® System and CCM® Therapy The Optimizer® system delivers CCM® therapy — the company's proprietary technology — to the heart, providing clinically meaningful improvement to quality of life for appropriate HF patients. CCM® therapy is designed to significantly improve heart contraction, allowing more oxygen-rich blood to be pushed out through the body[2]. CCM® therapy is indicated to improve six-minute hall walk, quality of life, and functional status of NYHA Class III HF patients who remain symptomatic despite guideline directed medical therapy, are not receiving CRT, and have a left ventricular ejection fraction ranging from 25 to 45 percent. CCM® is the brand name for cardiac contractility modulation — the non-excitatory electrical pulses delivered by the implantable Optimizer® device to improve heart contraction. CCM® therapy sends unique electrical pulses to the heart cells during the absolute refractory period. In doing so, CCM® helps the heart contract more forcibly. Impulse Dynamics® has completed numerous clinical studies, including several randomized controlled trials, the results of which appeared in more than 100 publications in leading medical journals. About Impulse Dynamics® Impulse Dynamics® is dedicated to advancing the treatment of HF for patients and the healthcare providers who care for them. The company pioneered its proprietary CCM® therapy, which uses the Optimizer® technology platform to improve quality of life in HF patients. CCM® therapy is delivered through the Optimizer® system, which includes an implantable pulse generator (IPG) implanted in a minimally invasive procedure and approved for commercial use in the United States and countries worldwide. More than 10,000 patients have received the therapy as part of clinical trials and real-world use, where it is shown to be safe and effective for HF patients with debilitating symptoms who otherwise have few effective options available to them. The company is currently engaged in another significant clinical trial called AIM HIGHer. The AIM HIGHer clinical trial is a multicenter study with the objective to evaluate the safety and efficacy of CCM® therapy in patients with symptomatic HF with an ejection fraction of 40 to 70 percent (inclusive). The trial is currently in its initial enrollment phase. To learn more, visit , or follow the company on LinkedIn, X (formerly Twitter), and Facebook. ### References:
